Please assess the completion status of the following clinical trial:

Trial Title: Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documentation by MR of a gadolinium-enhancing intraparenchymal mass consistent with malignant glioma.~* Frozen section diagnosis of WHO Grade IV glioma, confirmed with permanent section and immunopositive for IGF-1R.~* An Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 or a Karnofsky Performance Score (KPS) of at least 60.~* Must be 18 years of age or older.~* Must sign an approved informed consent.~* Hemodynamically stable, consistent with Standard of Care values for patients undergoing elective tumor resection.~Exclusion Criteria:~* Females who are pregnant, nursing, or not inclined to use adequate contraceptive methods if necessary to prevent pregnancy during the study.~* An active second primary malignancy with the exception of basal cell or squamous cell skin carcinoma.~* Major concomitant medical illness inclusive of severe chronic obstructive pulmonary disease, multiple sclerosis, symptomatic coronary artery disease, heart failure, recent major cerebrovascular accident, brittle diabetes, renal dialysis, end stage liver disease, labile hypertension, or any autoimmune disorder.~* A history of heparin-induced thrombocytopenia or hypersensitivity to heparin, enoxaparin, or pork products.~* An abnormal International Normalized Ratio (INR) of greater than 1.3, if repeatable and refractory to correction by routine methods.~* Documented deep venous thrombosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): After protocol amendment dated 11 May 2017, all subjects enrolled into the trial will receive 20 chambers for 48 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).